Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer

Trial Profile

Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Axalimogene filolisbac (Primary) ; Durvalumab (Primary)
  • Indications Cervical cancer; Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Advaxis
  • Most Recent Events

    • 13 Jun 2017 According to an Advaxis media release, case study data from this trial presented at annual Investor & Analyst Day.
    • 09 Jan 2017 According to an Advaxis media release, updated data from this trial are expected in the second half of 2017.
    • 26 Sep 2016 According to an Advaxis media release, this trial will be poster presented at the Society for Immunotherapy of Cancer's (SITC) 31st Annual Meeting and Associated Programs, 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top